A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome.
WHIM-syndrome is an inherited immunodeficiency disorder with abnormal susceptibility to human papillomavirus (HPV) infection and diseases. We determined safety and immunogenicity to a quadrivalent HPV vaccine in WHIM-syndrome by detection of HPV-specific antibodies and lymphoproliferation. In virus-like-particle (VLP)-ELISA, a WHIM patient showed antibody titers up to 400 for HPV-6/11/16/18, whereas immuno-competent controls developed titers of 6400-25,600. In pseudovirion assays, the patient's neutralization titers ranged from 20 to 400 to the four HPV vaccine types, while titers of 1600-25,600 were detected in healthy vaccinees. Specific proliferation of PBMC of the WHIM patient to the HPV vaccine was demonstrated. This first report on response to HPV vaccination in WHIM-immunodeficiency highlights that patients with WHIM-syndrome, and probably other immunodeficiencies, may benefit from HPV immunoprophylaxis.
Handisurya
Alessandra
A
Laboratory of Viral Oncology (LVO), Division of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University Vienna, Vienna, Austria.
Schellenbacher
Christina
C
Reininger
Bärbel
B
Koszik
Frieder
F
Vyhnanek
Philipp
P
Heitger
Andreas
A
Kirnbauer
Reinhard
R
Förster-Waldl
Elisabeth
E
D049109:Cell Proliferation; D002648:Child; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology*; D056724:Immunity, Humoral / Q000276:immunology*; D007153:Immunologic Deficiency Syndromes / Q000151:congenital / Q000235:genetics / Q000276:immunology*; D008214:Lymphocytes / Q000276:immunology; D009500:Neutralization Tests; D053918:Papillomavirus Vaccines / Q000276:immunology*; D014771:Virion / Q000276:immunology
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines
MMWR Recomm Rep. 2006 Dec 1;55(RR-15):1-48
17136024
J Natl Cancer Inst. 1994 Apr 6;86(7):494-9
8133532
J Allergy Clin Immunol. 2005 Nov;116(5):1101-5
16275383
J Gen Virol. 2009 Jan;90(Pt 1):136-43
19088282
J Clin Invest. 2006 May;116(5):1167-73
16670757
Blood. 2004 Jul 15;104(2):444-52
15026312
Blood. 2000 Jan 1;95(1):320-7
10607719
J Virol. 2002 Aug;76(15):7832-42
12097595
Vaccine. 2007 Jun 21;25(26):4931-9
17499406
Blood. 2005 Mar 15;105(6):2449-57
15536153
Vaccine. 2007 May 22;25(21):4324-33
17445955
J Virol. 2009 Oct;83(19):10085-95
19640991
Vaccine. 2008 Dec 9;26(52):6844-51
18930097
Curr Allergy Asthma Rep. 2005 Sep;5(5):350-5
16091205
Am J Med. 1990 Nov;89(5):663-72
2239986
Lancet. 2009 Jul 25;374(9686):301-14
19586656
J Dtsch Dermatol Ges. 2009 May;7(5):453-66; quiz 466, 467
19302229
J Clin Invest. 2008 Mar;118(3):1074-84
18274673
Virology. 2004 Apr 10;321(2):205-16
15051381
Nat Genet. 2003 May;34(1):70-4
12692554
Exp Hematol. 2005 Apr;33(4):460-8
15781337
JAMA. 2007 Feb 28;297(8):813-9
17327523
J Immunol. 2006 Aug 15;177(4):2662-2670
16888028
Acta Paediatr Scand. 1980 Jul;69(4):549-51
6255734
J Infect Dis. 2009 Jul 15;200(2):166-71
19519255
Cancer Prev Res (Phila). 2009 Oct;2(10):868-78
19789295
N Engl J Med. 1964 Apr 2;270:699-704
14101065
N Engl J Med. 2003 Feb 6;348(6):518-27
12571259
J Virol. 1993 Dec;67(12):6929-36
8230414
Curr Opin Hematol. 2009 Jan;16(1):20-6
19057201
J Infect Dis. 2001 May 15;183(10):1485-93
11319684
Vaccine. 2008 Aug 19;26 Suppl 10:K53-61
18847557
N Engl J Med. 2009 Jul 16;361(3):271-8
19605832
Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12180-4
1334560
J Gen Virol. 1994 Sep;75 ( Pt 9):2445-9
8077946
Br J Cancer. 2006 Dec 4;95(11):1459-66
17117182
J Infect Dis. 2003 Jul 15;188(2):327-38
12854090
J Virol. 2004 Jan;78(2):751-7
14694107
N Engl J Med. 1977 Aug 4;297(5):241-5
195206
Methods Mol Med. 2005;119:445-62
16350417
Am J Med Genet. 2000 Apr 24;91(5):368-76
10767001
J Virol. 1995 Jun;69(6):3959-63
7745754